The group’s principal activities include research and developing new preclinical bioassay platforms for accelerating drug discovery, diagnostics and therapeutics. The group’s services include cancer drug testing in 3D HuBiogel assays, drug toxicity analysis, gene analysis and real-time 3D bioimaging and analysis. The group operates from the United States.
